In a subset of tumors harboring kinase cancer driver mutations, the selective and direct blocking of mutant BRAF-dependent downstream signaling to MEK-ERK is a remarkable feature of BRAFi [5,15]. This evidence concerns the gene MAP2K7 and cancer.